As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma, biotech, and industrial biology. Ainnocence is expanding partnerships, ...

Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific, they ...

The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows ...

Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...

Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines ...

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...

Scientists have found that antibodies stop UTI-causing E. coli by jamming or mimicking cell receptors, preventing bacterial ...

BOSTON, May 30, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today ...